Cacosmia and Cacogeusia in Patients with Persistent Anosmia and Ageusia due to COVID-19

Kübra Topal; Fatma Atalay; Ayhan Kars

doi:10.5152/ejra.2021.21032

Cacosmia and Cacogeusia in Patients with Persistent Anosmia and Ageusia due to COVID-19

Abstract

Objective: The most frequent symptoms in COVID-19 infection are fever, cough, and fatigue. Also, olfactory and gustatory disorders can be seen with the infection. Despite an abundance of studies reporting anosmia and ageusia, there are limited studies on the development of cacosmia and cacogeusia. This study aimed to contribute to the literature on this novel disease by reporting and evaluating cacosmia and cacogeusia patients. Methods: One hundred and twenty patients presenting to our clinic with loss of taste and smell after COVID-19 infection without subsequent improvement were examined in this study. Cacosmia and cacogeusia subsequently developed in 17 of these patients. Patients’ demographic characteristics such as age and gender, history of chronic disease, and smoking status were investigated. Laboratory tests and magnetic resonance imaging of the brain were performed. Results: Cacosmia and cacogeusia developed in 17 (14.1%) patients out of 120 patients who had persistent anosmia and ageusia after COVID-19. No significant difference was observed in terms of gender, but mean age was statistically significantly lower in the group developing cacosmia. Decreased olfactory bulb volume was observed in two patients, interpreted as secondary to the infection. Conclusion: Cacosmia and cacogeusia can develop in late COVID-19 and can significantly impair the quality of life of patients. There is no correlation between the severity of the disease and the rate of these symptoms. Currently, there is no efficient treatment for these patients. Further studies are required to reveal the underlying sensorineural pathology for the development of cacosmia and cacogeusia and treatment of these symptoms.

Keywords

References

Pappa S, Ntella V, Giannakas T, Giannakoulis VG, Papoutsi E, Katsaounou P. Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Brain Behav Immun. 2020;88:901-907.
Krajewska J, Krajewski W, Zub K, Zaton ´ ski T. COVID-19 in otolaryngologist practice: A review of current knowledge. Eur Arch Otorhinolaryngol. 2020;277:1885-1897.
Rockx B, Kuiken T, Herfst S, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science. 2020;368:1012-1015.
Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177-1179.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: A review article. Neurol Sci. 2020;41:1667-1671.
Lovato A, De Filippis C. Clinical presentation of COVID-19: A systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020;99:569-576.
Sayin I, Yazici ZM, Oz F, Akgul A. Otolaryngology-head and neck surgery perspective of COVID-19. Turkiye Klinikleri J Med Sci. 2020;40:120-124.

Hummel T, Whitcroft K, Andrews P, et al. Position paper on olfactory dysfunction. Rhinol Suppl. 2017;54:1-30.
Leopold D. Distortion of olfactory perception: Diagnosis and treatment. Chem Senses. 2002;27:611-615.
Kano T, Kanda K. Development and validation of a chemotherapy-induced taste alteration scale. Oncol Nurs Forum. 2013;40(2):E79-E85.
Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: A systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020;163:3-11.
Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: A cross-sectional study. Clin Infect Dis. 2020;71:889-890.
Bagheri SH, Asghari A, Farhadi M, et al. Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak in Iran. Med J Islam Repub Iran. 2020;34:62.
Tsuruoka S, Wakaumi M, Araki N, Ioka T, Sugimoto K, Fujimura A. Comparative study of taste disturbance by losartan and perindopril in healthy volunteers. J Clin Pharmacol. 2005;45:1319-1323.
Temmel AF, Quint C, Schickinger-Fischer B, Klimek L, Stoller E, Hummel T. Characteristics of olfactory disorders in relation to major causes of olfactoryloss. Arch Otolaryngol Head Neck Surg. 2002;128:635-641.
Klopfenstein T, Kadiane-Oussou NJ, Toko L, et al. Features of anosmia in COVID-19. Med Mal Infect. 2020;50:436-439.
Spinato G, Fabbris C, Polesel J, et al. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. JAMA. 2020;323:2089-2090.
Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome. Rhinology. 2020;58:299-301.
Eliezer M, Hautefort C, Hamel AL, et al. Sudden and complete olfactory loss of function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. 2020;146:674-675.
Aziz M, Goyal H, Haghbin H, Lee-Smith WM, Gajendran M, Perisetti A. The association of “loss of smell” to COVID-19: A systematic review and meta-analysis. Am J Med Sci. 2021;361:216-225.
Ismail II, Gad KA. Absent blood oxygen level-dependent functional magnetic resonance imaging activation of the orbitofrontal cortex in a patient with persistent cacosmia and cacogeusia after COVID-19 infection. JAMA Neurol. 2021;78:609-610.

Details

Primary Language

English

Subjects

Otorhinolaryngology

Journal Section

Research Article

Authors

Kübra Topal
0000-0003-2179-4180
Türkiye

Fatma Atalay This is me
0000-0002-0344-1982
Türkiye

Ayhan Kars
0000-0003-4580-315X
Türkiye

Publication Date

December 25, 2021

Submission Date

June 26, 2021

Acceptance Date

September 20, 2021

Published in Issue

Year 2021 Volume: 4 Number: 3

DOI

https://doi.org/10.5152/ejra.2021.21032

IZ

https://izlik.org/JA24ZD93LM

Cite

RIS / Bibtex

APA

Topal, K., Atalay, F., & Kars, A. (2021). Cacosmia and Cacogeusia in Patients with Persistent Anosmia and Ageusia due to COVID-19. European Journal of Rhinology and Allergy, 4(3), 87-90. https://doi.org/10.5152/ejra.2021.21032

AMA

1.Topal K, Atalay F, Kars A. Cacosmia and Cacogeusia in Patients with Persistent Anosmia and Ageusia due to COVID-19. Eur J Rhinol Allergy. 2021;4(3):87-90. doi:10.5152/ejra.2021.21032

Chicago

Topal, Kübra, Fatma Atalay, and Ayhan Kars. 2021. “Cacosmia and Cacogeusia in Patients With Persistent Anosmia and Ageusia Due to COVID-19”. European Journal of Rhinology and Allergy 4 (3): 87-90. https://doi.org/10.5152/ejra.2021.21032.

EndNote

Topal K, Atalay F, Kars A (December 1, 2021) Cacosmia and Cacogeusia in Patients with Persistent Anosmia and Ageusia due to COVID-19. European Journal of Rhinology and Allergy 4 3 87–90.

IEEE

[1]K. Topal, F. Atalay, and A. Kars, “Cacosmia and Cacogeusia in Patients with Persistent Anosmia and Ageusia due to COVID-19”, Eur J Rhinol Allergy, vol. 4, no. 3, pp. 87–90, Dec. 2021, doi: 10.5152/ejra.2021.21032.

ISNAD

Topal, Kübra - Atalay, Fatma - Kars, Ayhan. “Cacosmia and Cacogeusia in Patients With Persistent Anosmia and Ageusia Due to COVID-19”. European Journal of Rhinology and Allergy 4/3 (December 1, 2021): 87-90. https://doi.org/10.5152/ejra.2021.21032.

JAMA

1.Topal K, Atalay F, Kars A. Cacosmia and Cacogeusia in Patients with Persistent Anosmia and Ageusia due to COVID-19. Eur J Rhinol Allergy. 2021;4:87–90.

MLA

Topal, Kübra, et al. “Cacosmia and Cacogeusia in Patients With Persistent Anosmia and Ageusia Due to COVID-19”. European Journal of Rhinology and Allergy, vol. 4, no. 3, Dec. 2021, pp. 87-90, doi:10.5152/ejra.2021.21032.

Vancouver

1.Kübra Topal, Fatma Atalay, Ayhan Kars. Cacosmia and Cacogeusia in Patients with Persistent Anosmia and Ageusia due to COVID-19. Eur J Rhinol Allergy. 2021 Dec. 1;4(3):87-90. doi:10.5152/ejra.2021.21032